Joachim Steffens,Petra Anheuser,Benedikt Becker et al.
Joachim Steffens et al.
Axel Heidenreich,Heiko Wunderlich
Axel Heidenreich
[Indication and outcome of salvage surgery for urogenital malignancies] [0.03%]
挽救性手术在泌尿生殖系肿瘤中的应用及结局分析
Julian Heidenreich,David Pfister,Olivia Steenbock et al.
Julian Heidenreich et al.
Based on the available data from mostly retrospective clinical studies, the indication for salvage surgery for tumors of the urogenital tract must be very strictly assessed by weighing the oncological benefit and possible therapy-associated...
[Between tablet and teamwork : Digital competence as a part of professional nursing] [0.03%]
[.between tablet and teamwork: digital competence as part of professional nursing]
Sabine Bohnet-Joschko,Katharina Loboiko
Sabine Bohnet-Joschko
[Palliative medicine and integrative medicine as complementary approaches in uro-oncological care] [0.03%]
[姑息治疗和整合医学在泌尿系统肿瘤治疗中的互补作用]
Petra Klose,Petra Voiß,Martje Voswinkel et al.
Petra Klose et al.
Background: Uro-oncological diseases have negative long-term consequences for physical, functional, psychological, and socioeconomic well-being. A common focus of palliative and integrative medicine is improving quality o...
[Erectile dysfunction-It is time to act! : Practical tips and current guideline recommendations for diagnostics and treatment of a still underestimated disease] [0.03%]
[阳痿--是时候行动了！诊断和治疗仍然被低估的疾病的实用建议和当前指南推荐]
Saskia Carmen Morgenstern
Saskia Carmen Morgenstern
The main risk factors for erectile dysfunction (ED) are age, smoking, metabolic syndrome, cardiovascular diseases, diabetes and status following pelvic surgery. The diagnostics include a (psychosexual) medical history, a physical examinatio...
Elli Husso,Maike Wittmann,Isabella Maria Zraik
Elli Husso
Background: Modern treatments in uro-oncology are increasingly based on therapeutics with complex metabolism in the human body and are associated with an increased risk of drug interactions. ...
[Treatment options in rare urological tumors: potential of molecular tumor boards] [0.03%]
罕见泌尿肿瘤的治疗选择：分子肿瘤委员会的潜力
Steffen Rausch,Isabel Heidegger,Johannes Linxweiler et al.
Steffen Rausch et al.
Rare urological tumors such as neuroendocrine prostate cancer, non-clear cell renal cell carcinoma, penile carcinoma, and non-urothelial bladder tumors are defined by low incidence, biological heterogeneity, and limited evidence-based treat...
Elke Oberhofer
Elke Oberhofer
[Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer] [0.03%]
[聚(腺苷二磷酸核糖)多聚酶抑制剂联合治疗转移性去势抵抗性前列腺癌]
Carsten Ohlmann,Christian Gratzke,Laura-Maria Krabbe
Carsten Ohlmann
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge. Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) combined with new hormonal agents (NHA) offer novel tre...